CapsoVision, Inc. (NASDAQ: CV) shares were strong in the early going on Friday. The company, a commercial-stage medical technology firm developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity financing pursuant to a securities purchase agreement entered into by the Company with selected accredited investors on March 16, 2026 for such investors to purchase shares of common stock of the Company.
Pursuant to the securities purchase agreement, the Company has agreed to sell 2,867,089 shares of common stock of the Company, with par value $0.001 per share, at $4.883 per share, which represents a 5% discount to the March 16 closing price, as per the terms of the agreement.
The closing occurred on March 16, with approximately $14 million aggregate gross proceeds. The Company expects to use the net proceeds from the Private Placement for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, and working capital.
CV shares gained 48 cents, or 7.8%, to $6.66.
